Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2001

01-02-2001 | Review

The role of bisphosphonates in breast cancer: Actions of bisphosphonates in animal models of breast cancer

Authors: Susan S Padalecki, Theresa A Guise

Published in: Breast Cancer Research | Issue 1/2001

Login to get access

Abstract

The skeleton is the most common site of breast cancer metastases. These bone metastases are usually osteolytic and cause significant morbidity. Bisphosphonates, potent inhibitors of bone resorption, reduce skeletal morbidity in breast cancer patients with bone metastases. Animal studies with bisphosphonates are crucial to understanding the mechanisms by which these compounds affect bone and tumor cells in vivo. Such animal models of breast cancer that are used to test the efficacy of bisphosphonates are discussed. These studies may offer insight into the treatment of other tumor types that frequently metastasize to bone.
Literature
1.
Paget S: The distribution of secondary growths in cancer of the breast. Lancet. 1889, 1: 571-572.CrossRef
2.
Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR: Evidence for a causal role of parathyroid hormone-related protein in pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996, 98: 1544-1549.CrossRefPubMedPubMedCentral
3.
Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999, 103: 197-206.CrossRefPubMedPubMedCentral
4.
Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol. 1997, 98: 665-672. 10.1046/j.1365-2141.1997.2713086.x.CrossRefPubMed
5.
Shipman CM, Croucher PI, Russell RGR, Helfrich MA, Rogers MJ: The bisphosphonate incadronate (YM 175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998, 58: 5294-5297.PubMed
6.
Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 1998, 12: 220-229. 10.1038/sj.leu.2400892.CrossRefPubMed
7.
Busch M, Rave-Frank M, Hille A, Duhmke E: Influence of clodronate on breast cancer cells in vitro. Eur J Med Res. 1998, 3: 427-431.PubMed
8.
Fromigue D, Siwek B, Body JJ: Bisphosphonates inhibit breast cancer cell proliferation. Calcif Tissue Int. 1999, 64: P261-
9.
Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonene J, Auriola S, Chilton KM, Russell RG: Molecular mechanism of action of bisphosphonates. Bone. 1999, 24: 73S-79S. 10.1016/S8756-3282(99)00070-8.CrossRefPubMed
10.
11.
Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001, 296: 235-242.PubMed
12.
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000, 88: 2961-2978. 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.3.CO;2-C.CrossRefPubMed
13.
Derenne S, Amiot M, Barille S, Bollette M, Robillard N, Berthaud P, Harousseau JL, Bataille R: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res. 1999, 14: 2048-2056.CrossRefPubMed
14.
van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, Papapoulos S: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996, 98: 698-705.CrossRefPubMedPubMedCentral
15.
Senaratne SG, Colston KW: Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res. 2002, 4: 18-23. 10.1186/bcr412.CrossRefPubMed
16.
Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000, 82: 1459-1468.CrossRefPubMedPubMedCentral
17.
Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrix. Cancer Res. 1997, 57: 3890-3894.PubMed
18.
Selander KS, Mönkkönen J, Karhukorpi EK, Harkonen P, Han-nuniemi R, Vaanenen HK: Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol. 1996, 50: 1127-1138.PubMed
19.
Virtanen SS, Väänänen HK, Härkönen PL, Lakkakorpi PT: Effects of alendronate on adhesion and invasion of breast and prostate cancer cells. Calcif Tissue Int. 2001, 66: S79-
20.
Yoneda T, Sasaki A, Mundy GR: Osteolytic bone disease in breast cancer. Breast Cancer Res Treat. 2001, 32: 73-84.CrossRef
21.
Sasaki A, Boyce BF, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: Bisphosphonate risedronate reduces metastastic human breast cancer burden in nude mice. Cancer Res. 1995, 55: 3551-3557.PubMed
22.
Sasaki A, Kitamura K, Alcalde RE, Tanaka T, Suzuki A, Etoh Y, Matsumura T: Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer. 1998, 77: 279-285. 10.1002/(SICI)1097-0215(19980717)77:2<279::AID-IJC18>3.0.CO;2-6.CrossRefPubMed
23.
Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiragu T: Actions of bisphosphonates on bone metastases in animal models of breast carcinoma. Cancer Suppl. 2000, 88: 2979-2988. 10.1002/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U.CrossRef
24.
Kostenuik PJ, Ori FW, Suyama K, Singh G: Increased growth rate and tumor burden of spontaneously metastastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res. 1993, 53: 5452-5457.PubMed
25.
Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001, 61: 4418-4424.PubMed
26.
Mundy GR, Yoneda T, Hiraga T: Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenviroment. Semin Oncol. 2001, 28(suppl 6): 35-44. 10.1053/sonc.2001.24158.CrossRef
27.
Hall DG, Stoico G: Effect of the bisphosphonate Risedronate on bone metastases in rat mammary adenocarcinoma model system. J Bone Miner Res. 1994, 9: 221-230.CrossRefPubMed
28.
Krempien B, Diel IJ, Jockle-Kretz B, Buchele R, Andre L: The Walker Carcinosarcoma 256 model of bone metastases, Influence of skeletal metabolism on the development of bone metastases. Verh Dtsch Ges Pathol. 1984, 68: 211-216.
29.
Krempien B, Manegold C: Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP. Cancer. 1993, 72: 91-98.CrossRefPubMed
30.
Krempien B, Wingen F, Eichmann T, Muller M, Schmahl D: Protective effects of a prophylactic treatment with bisphosphonate 3-amino-1-hydroxypropanel, 1 bisphonic acid on the development of tumor osteopathies in rat: experimental studies with the Walker Carcinosarcoma 256. Oncology. 1998, 45: 41-46. 10.1159/000009922.CrossRef
31.
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducting skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996, 335: 1785-1791. 10.1056/NEJM199612123352401.CrossRefPubMed
32.
van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol. 1993, 11: 491-498.PubMed
33.
Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases – Long term followup of two randomized, placebo-controlled trials. Cancer. 2000, 88: 1082-1090. 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z.CrossRefPubMed
34.
Kurth AHA, Kim S-Z, Sedlmeyer I, Hovy L, Bauss F: Treatment with ibandronate preserves bone in experimental tumor-induced bone loss. J Bone Joint Surg. 2000, 82-B: 126-130. 10.1302/0301-620X.82B1.9483.CrossRef
35.
Green JR: Anti-tumor potential of bisphosphonates. Med Klin. 2000, 95: 23-28.
36.
Diel IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998, 339: 357-363. 10.1056/NEJM199808063390601.CrossRefPubMed
37.
Saarto T, Blomqvist C, Virkkunen P, Elomaa I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001, 19: 10-17.PubMed
Metadata
Title
The role of bisphosphonates in breast cancer: Actions of bisphosphonates in animal models of breast cancer
Authors
Susan S Padalecki
Theresa A Guise
Publication date
01-02-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2001
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr415

Other articles of this Issue 1/2001

Breast Cancer Research 1/2001 Go to the issue

Paper Report

Gene expression profiling

Paper Report

Primary chemotherapy with CEF-infu

Paper Report

Gene expression signatures may predict clinical outcome

Paper Report

Sequential tumour biopsies in phase I trials

Paper Report

The problem of trastuzumab (Herceptin) resistance: a role for IGF-1R?

Non-peer-reviewed research

Lysosomal Enzyme-Induced Cell Death in MCF7 and Mammary Gland Cells.
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits